Generic Name and Formulations:
Flucytosine 250mg, 500mg; caps.
Valeant Pharmaceuticals, Inc
Indications for ANCOBON:
In combination with amphotericin B: Candida infections in septicemia, endocarditis, UTIs and pulmonary infections; cryptococcus infections in meningitis, pulmonary, septicemia, and UTIs.
Adults and Children:
50–150mg/kg per day given in divided doses every 6 hours. To minimize GI upset, give a few capsules at a time over 15 minutes. Renal impairment: give initial dose at lower range.
Renal or hepatic impairment. Monitor electrolytes, blood count, renal and hepatic function before and during therapy. Bone marrow depression (eg, hematologic disease, history or currently treated with radiation or bone marrow depressants). Pregnancy (Cat.C). Nursing mothers.
Antagonized by cytosine arabinoside. May be potentiated by drugs that impair glomerular filtration.
Cardiac events, chest pain, dyspnea, GI upset, abdominal pain, hepatic dysfunction, elevated creatinine and BUN, blood dyscrasias, ataxia, headache, confusion, fatigue, hypoglycemia, hypokalemia, rash, allergic reactions, others.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies